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Summary.-Serum angiotensin-converting enzyme (SACE) in 141 patients with
newly detected primary lung cancer was 22-1 +6-1 nmol/ml/min (mean + s.d.); lower
than in healthy controls (24.4 +6-2 nmol/ml/min, P<0.02). No correlation was found
between SACE and sex, age, site of cancer, histological type, or lung function.
After subdivision of the patients according to increasing SACE levels: < 16.0
(mean SACE of lung cancer -s.d.), 16-0-22-0,22-1-28-2, and >28-2 nmol/ml/min (mean
SACE of lung cancer+s.d.) there was a strong association (P <0001) between SACE
level and the proportion of patients who were radically operated without relapse
during8-22 months follow-up. None of23 patients within the lowest SACE range were
cured, even though 7 were referred for operation after preoperative examination. In
contrast, 10/25 patients (40%O) within the highest SACE range were cured.
The results suggest that low SACE is associated with poor prognosis in lung can-
cer, even in patients who are judged as being operable on preoperative evaluation;
and measurement of preoperative SACE in lung cancer may be a useful prognostic
indicator in this disorder.
A PROBLEM in evaluating lung-cancer
patients for surgical treatment is that
prognosis is poor, despite considerable
technical and pharmacological improve-
ment (Br. Med. J., Editorial, 1975). Thus
even if a tumour is judged to be resectable
on preoperative examination, the patient
is often inoperable at thoracotomy; and
even if the cancer is radically removed,
the relapse rate and frequency ofclinically
unsuspected distant spread of cancer is
high.
Since even an explorative thoracotomy
is not without risk and discomfort for the
patient, improvement in the methods for
selecting patients for operation would be
valuable.
Angiotensin-converting enzyme (ACE)
is a membrane-bound glycoprotein found
in endothelium throughout the body, but
mainly in the lung vasculature. Here it has
been demonstrated in pinocytic vesicles
of the capillary endothelium (Ryan et al.,
1975). The physiological role of ACE is at
least two-fold: (1) to convert inactive
angiotensin I into the vasopressor angio-
tensin II, and (2) to participate in the
degradation of bradykinin (hence the
synonymous II "kininase") (Soffer, 1976).
Thus, the enzyme plays an important part
in the metabolic and paraendocrine func-
tions ofthe lung (Bakhle & Vane, 1977).
The level of serum-ACE (SACE) in
lung cancer is generally reported to be
low. Although statistical significance was
not reached in an earlier series of 40
patients from our Department (R0mer,
1980b), significantly lowered SACE in
lung cancer has been reported by other
investigators (Ashutosh & Keighley, 1976;
Gronhagen-Riska, 1979; Lieberman et al.,
1979; Silverstein et al., 1977). In only one
paper a rather high SACE was noted
(Turton et al., 1979). However, detailed
analysis was not possible because most of
the series were small, and had insufficient
clinical data.
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examine the hypothesis that the pre-
operative level of SACE is associated with
prognosis in lung cancer, expressed by the
number of patients who were referred for
surgery, radically operated and free of
cancer, respectively.
METHODS
Patients.-A total of 150 patients with
biopsy-proven, newly detected primary lung
cancer were examined (Table I). All patients
were untreated at the time of examination
except for one on prednisone. Kidney funic-
tion was normal in all patients but one. Sex,
age, site of cancer and pathology are shown
in Table II.
The subdivision of the patients is shown in
Table I. Of 150 patients nine were only used
for examination of SACE pre- and post-
operatively. They were examined late in the
study, and were excluded from other calcula-
tions because oflack offollow-up time. Thus,
the observations on clinical variables and
prognosis were made on 141 consecutive
patients. Ofthese, 54 (38%) were referred for
surgery and underwent operation (Group A).
Of these the operation was radical (tumour
completely removed without residual cancer)
in 33 (61%) (Group B). Theradically operated
and surviving patients were followed for
8-22 months (mean 16). Relapse (local
recurrence or distant metastases) occurred in
8 of these, leaving 25 patients (18%) free of
cancer or "cured" (Group C). Eight of these
died from postoperative complications. Thus,
17 were alive and free of cancer during the
period of observation. Number of deaths was
only quoted in radically operated patients
without relapse of cancer. Among radically
operated patients, none were treated with
radiation or chemotherapy. Any patient was
lost from follow-up when he had relapse or
died, and the results ofradiation and chemo-
therapy were not considered.
Mediastino-bronchoscopy was performed in
all patients who were not obviously inoper-
able. Liver andbone scans wereroutinely used
as screening methods for extrapulmonary
metastasis. Lung function was examined with
respect to arterial blood oxygen and carbon
dioxide, pH, lung capacities and volumes,
airwayresistance anddiffusion capacity.
Evaluation and treatment, and determina-
tion of SACE were done independently.
Analysis.-SACE was analyzed using the
method of Cushman & Cheung (1971) as
modified by Lieberman (1975, 1976). All
analyses were in duplicate. Serum was stored
at -20°C until analysis, and enzyme activity
was unchanged after 2 years' storage.
Enzyme activity in a reference series of 116
healthy adults aged 18-65 years was 12-0-36-8
nmol/ml/min units (mean 24-4 +2 s.d.).
Coefficient of variation was 0-03 intra-assay
and 0-05 inter-assay.
Statistics (Documenta Geigy, 1970).-Dif-
ferences between mean values were calculated
using Student's t test (samples >25-50) or
the Mann-Whitneyrank sum test (samples <
25-50). The Wilcoxon signed rank test
was used for paired values. Proportions 2 x2
contingency tables were examined by Fisher's
exact test or the x2 test with Yates's correc-
tion. Outcome of patients with respect to
SACE levels was examined with a x2 test
with one degree of freedom (Bradford Hill,
1971). Correlation was tested with the Spear-
man's rho. SACE was expressed as mean
+ 1 s.d. The significance level was 5%.
RESULTS
SACE in lung cancer and healthy controls
Among 141 patients with lung cancer
SACE was 22-1 + 6-1 nmol/ml/min (range
7-0-33-7). This was lower than the figure
for healthy persons (P< 0-02). No correla-
tion was found between age and SACE in
persons with lung cancer or the controls.
Four patients with lung cancer had
sarcoid-like non-caseating epithelioid
granulomas in lymph nodes draining
cancer. SACE in these patients was 16-2-
29-9 nmol/ml/min.
Clinical features and outcome
These are shown in Table II. No associa-
tion between outcome and sex, age or site
of cancer was found. Patients with ana-
plastic carcinoma showed a different pat-
tern from those with non-anaplastic neo-
plasms, because a smaller proportion was
found suitable for surgery (19% vs 48%).
Patients who died or had relapse of cancer
after operation
Among the 33 patients radically opera-
ted, postoperative death not due to relapse
occurred in 8 (24%) within 2-12 weeks
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TABLE I. Survey of the series, defining the subgroups ofpatients
Patients
Total series
Patients only examined with respect to pre-
and postoperative SACE
Consecutive patients who constituted the
main series used for all other calculations
Inoperable at preoperative examination
Referred for surgery (Group A)
Operation not radical
Operation radical, tumour completely
removed (Group B)
Relapse (recurrence or metastases)
Patients free ofcancer ("cured")
during follow-up (Group C)
Postoperative deaths without residual
cancer
Curedpatients who survived during
follow-up
SACE
nmol/ml/min
No. (mean +s.d.)
150
p Remarks
9
1441 22-1+6-1
87 21-3 + 6-0 N
54 23-2 + 5-6 N
21 22-0 + 6-4
N.
33 24-0 + 5-6 J
8 18-8+5-4
1
< 0-01
25 25-6+4-7 J
8 28-1+3-9
Examination ofcorrelation
between SACE andlung-
function tests in 47
patients
Serialanalysis in 10patients .S.
.S.
<0-01
17 24-5+4-7
TABLE II.-Clinical and demographical characteristics of 141 patients with lung cancer, as
related to outcome. Cured patients denotes allpatientsfree ofcancer, irrespective ofdeath
frompostoperative complications
No. of
patients
(% of total)
Lung cancer, total 141
Sex
M
F
Age (years)
-49
50-59
60-69
70-
Side localization
R
L
R+L
Pathology
Anaplastic
Epidermoid
Adenocarcinoma
Other
116 (82)
25 (18)
6 (4)
34 (24)
69 (49)
32 (22)
79 (56)
60 (43)
2 (1)
Group A
No. referred
for surgery
(%)
54 (38)
48 (42)
6 (24)
4 (67)
12 (35)
25 (36)
13 (41)
27 (34)
27 (54)
0
47 (33) 9 (19)
46 (33) 26 (58)
26 (18) 10 (38)
22 (16) 9 (41)
Group B
Operation
radical
(%)
33 (23)
29 (25)
4 (16)
3 (50)
6 (18)
16 (23)
8 (25)
17 (22)
16 (27)
5 (11)
14 (30)
9 (35)
5 (23)
Group C
Cured
Relapse (%)
8 25 (18)
8 21 (18)
0 4 (16)
0
3
4
1
3 (50)
3 (9)
12 (17)
7 (22)
1 16 (20)
7 9 (15)
0
1
2
3
2
4 (9)
12 (26)
6 (23)
3 (14)
(mean 6). Another 8 patients had relapse
after 2-40 weeks (mean 21). SACE in the
former group was significantly higher than
in the latter (Table I).
The patients who died from postopera-
tive complications (and without evidence
of cancer) were not included in the ob-
served prognosis of cancer (Tables II, III
and V) because the study only dealt with
the cancer risk and cancer cure. However,
the cancer risk among these patients was
calculated according to cancer risk in the
SACE level to which they belonged (see
later).
Cured/
Operated
(%)
46
44
67
75
25
48
54
59
33
44
46
60
33
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TABLE III.-Clinical and demographical characteristics of 141 patients with lung cancer,
as related to SACE levels
SACE
No. of nmol/ml/min
patients (mean+s.d.)
Lung cancer, total 141
No. of patients from each SACE level (%)
t.E
<16-0 160-220 221-282 >282
22 1+6 1 23 (16) 45 (32) 48 (34) 25 (18)
Sex
M
F
Age (years)
-49
50-59
60-69
70-
Side localization
R
L
Pathology
Anaplastic
Epidermoid
Adenocarcinoma
Other
116 21 9+6 1 20 (17)
25 230+55 3 (12)
6
34
69
32
25 7+3 8
20 0+ 6 8
22-0+ 6-7
217+ 64
0
9 (27)
9 (13)
5 (16)
37 (32)
8 (32)
2 (33)
14 (41)
18 (26)
11 (34)
40 (35) 19 (16)
8 (32) 6 (24)
2 (33) 2 (33)
7 (21) 4 (12)
30 (44) 12 (17)
9 (28) 7 (22)
79 21-7+6-0 13 (17) 28 (35) 26 (33)
60 22-4+6 2 10 (17) 17 (28) 20 (30)
47
46
26
22
229 + 5-9
21-0+6-7
22-7+5-8
21-8+5-3
8 (17)
9 (20)
5 (19)
1 (4)
12 (26) 19 (40)
17 (37) 12 (26)
5 (19) 12 (16)
11 (50) 5 (23)
12 (15)
13 (22)
8 (17)
18 (17)
4 (15)
5 (23)
SACE vs clinicalfeatures
In a sample of 47 patients no correlation
was found between SACE and pulmonary
function. Table III. shows that no sig-
nificant difference in mean SACE was
found as regards sex, age, site or histo-
logical type of cancer. In the Table the
patients were divided according to SACE
levels as follows:
Mean SACE in 141 patients with lung
cancer was 22-1 nmol/ml/min (s.d. = 6.1).
Instead ofusing the limits ofthe reference
series, the patients were divided into sub-
groups using the figures for lung cancer
as astartingpointbyadding orsubtracting
1 s.d. to or from the mean of 22-1 units.
In this way the limits used in Tables Ill-V
and Fig. 1 were reached: 16-0 (mean -
s.d.), 22-1 (mean) and 28-2 (mean+s.d.).
Comparing with the control series, the
figure of 16-0 units was approximately the
mean (24.4) minus 1-5 s.d. (s.d. = 6-2).
Outcome related to SACE levels
Fig. 1 and Table IV demonstrate the
outcome in 141 patients as related to
enzyme levels. The following associations
were found:
(1) At preoperative evaluation a gradu-
ally increasing proportion (from 30% to
60%) was referred for surgery according
to SACE levels (X2 3X970, d.f. = 1, P<
0.05).
n50
0
30
c16.0 16.0 - 22.0 22.1 - 28.2 >28.2
S-Angiotensin converting enzyme (nmol/mi/min)
Fim. 1.-Outcome in 141 patients with lung
cancer, as related to levels of SACE. Cured
patients include radically operated patients
without relapse of cancer. A calculated risk
of cancer among postoperative deaths is
included (see text).
C] Total no. of patients; [flf patients
referred for surgery; nJ operation radical;
* cured patients.
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TABLE IV. SACE levels and their association with results of preoperative evaluation,
operation and subsequentfollow-up ofradically operated patients
SACE levels (nmol/ml/min)
(a) Total no. of patienits (n= 141)
(b) Operation (n=54) (Group A)
(c) Radical operation (n = 33) (Group B)
(d) Postoperative deaths in radically
operated patients (n=8)
(e) Relapse (rn=8)
(f) Observed no. of "cured" patients
(Group C) (c-e)
(g) Surviving patients (c-d)
(h) Relapse among surviving patieints (e/g)
(i) Expected no. of relapses among
cured patients who died
postoperatively (h x (1)
(k) Expected relapse (i +e)
(1) Calculatecd no. of "cured'
patients (c -k)
Cured patients related to
I. Total no. (n = 141)
2. Operated patieints (n = 54)
3. Radically operated patients (n= 33)
Surviving an(l curedl patients (n = 17)
da-
< 16-0
No. (%)
23
7/23 (30)
3/7 (43)
0
3
3
3/3 (100)
100 x 0
=0
3 + 0
=3
()
(0)
((0))
I,))
16-0-22-0
-iA
No. (0)
45
15/45 (33)
9/15 (60)
3
6
8
3/8 (37 5)
37-5 x I
=0-38
:3+0-38
= 3-38
5i62
(12-5)
(37.5)
(62 4)
22-1-28-2
-T
No. (%)
48
17/48 (35)
10/17 (59)
1
9
8
1/8 (125)
12-5 x 2
=0-25
1 +0 25
1-25
S-75
(18 2)
(51-5)
(87.5)
>282
- -TA
No. (%)
25
15/25 (60)
11/15 (73)
P
< 0*05
N.S.
5
10
6
1/6 (16-7)
< 0-001
16-7 x 5
=0-84
1+0-84
1-84
9-16
(36 6)
(61.1)
(83 3)
< 0-001
<0-01
N.S.
0/23 (0) 5/45 (11-1) 7/48 (14-6) 5/25 (20-0) <005
The observe(d number of relapses is indicated as are the calculated risk of relapse among patients who
(lle(l from postoperative complications. The term "cured patients" under (f) is used for radically operate(l
p)atients without relapse of caneer, irrespective of postoperative deaths from other causes.
(2) A similar trend (43-73o) was found
regarding the proportion radically opera-
ted patients to the total operated on, but
it was not significant (X2 1X608, d.f. = 1,
P>0.05).
As regards outcome in 33 patients who
were radically operated (Group B) an
identical association between outcome and
enzyme level was found. However, 8
patients from this group died within 2-12
weeks, from post-operative complications
(cardio-respiratory failure) without any
signs of cancer at necropsy. With respect
to cancer these patients were cured. But
the observed number of cured patients
(dead plus alive) had to be corrected for
their risk of relapse, if they had had an
observation time as long as the survivors.
Therefore, their theoretical risk ofrelapse
as related to SACE level was calculated on
the assumption that the risk was the same
as that in the surviving patients from the
SACE level (Table IV). Thus, the results
were:
(3) Nobody with SACE < 16-0 units was
cured, though 7/23 (30%o) were judged
operable at preoperative evaluation;
(4) the proportion cured was signi-
ficantly smaller in patients with SACE
<16-0 units (0/23=0%, 950o confidence
limits 0-15) than in patients with SACE
> 28*2 units (9.2/25 =3666%, confidence
limits 18-58);
(5) the proportion of operated patients
who were cured was correlated with
increasing SACE level (X2 6X962, d.f.=1,
P < 0X01);
(6) the proportion of all patients cured
was strongly correlated to increasing
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enzyme level (X2 11X712, d.f.= 1, P
<0-001);
(7) The proportion cured and surviving
(n = 17) out of all patients was also corre-
lated with increasing enzyme levels (X2
4X714, d.f. = 1, P < 0-05).
SACE and clinicalfeatures versusprognosis
Combining data in Tables II and III,
SACE level was compared with sex, age,
site of cancer and histological type to
determine any effect on outcome. This
procedure produced small subgroups un-
suitable for statistical calculations, but a
uniform pattern emerged. The groups
with lowest enzyme level had the worst
prognosis. The predictive value of SACE
< 16-0 units for cure rate was even
stronger than the occurrence of anaplastic
carcinoma.
Course ofSACE in incurablepatients
In 8 untreated unoperated patients,
SACE was analysed twice or more, with an
interval of weeks to months (mean 4
months). The enzyme activity decreased
in all cases, from a SACE of 20'9 + 8-9
units at first examination to 1841 + 8-2
units at last examination (P < 002). The
decline was about 3% a month, and regres-
sion analysis showed a relationship be-
tweenlengthoftimebetweenbloodsamples
and the percentage decline of SACE
(P < 0*02).
Two inoperable patients who were
treated with chemotherapy and irradia-
25
c
E
0)
E
1-
N
c
a)
CD
C
I.. 0
C:
0
C
c a)
20
15 -
10 -
8x-
Before
operation
After
operation
FIG. 2. Pre- and postoperative SACE in 9
patients un(lergoing thoracotomy for lung
cancer (P < 0(05).
tion showed an increasing enzyme activity
after therapy and tumour regression.
SACE increased from ] &8 to 26-5 units
and from 21 8 to 24*0 units, respectively.
TABLE V.-Type ofoperation, SACE and outcome in 54 patients undergoing operationfor
lung cancer
SACE
nmol/ml/min
n (mean+s.d.) P
Pneumectomy 22 22-4 + 4-6
N.S.
Lobectomy 23 25-5 + 6-2 J 1
Explorative <0-02
thoracotomy 9 191+63 J
Total 54
13
WI'
23-2+5-6
'atients
tLh SACE Operation
< 16-0 ra(lical Cured*
(°/) (o%) (%) P
2 (9) 13 (59) 8 (36)
<0-05
2 (9) 20 (87) 17 (74)
N.S.
3 (33) 0 0 j
7 (13) 33 (61) 25 (46)
* Cured patients denotes all patients free of cancer, irrespective of dleath from postoperative complications.
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SACE in patients undergoing operation
The relationship between surgical pro-
cedures, SACE and outcome is shown in
Table V.
In an additional 9 patients, SACE was
analysed before operation and 3 or 6 days
after operation. SACE showed a small
decline from 16-7 + 4-6 units preopera-
tively to 14-5 + 3-5 postoperatively (P
< 0 02) independently of the extent and
type of operation (Fig. 2).
DISCUSSION
The present results have demonstrated
a strong association between preoperative
SACE level and outcome in patients with
lung cancer, suggesting that low SACE
may be an indicator ofinoperability. Thus,
nobody with SACE lower than the mean
for lung cancer-1 s.d. was cured.
Both a time-dependent decreasing
SACE in inoperable patients, an increasing
SACE in patients undergoing successful
chemotherapy, and the relationship be-
tween enzyme levels and prognosis of can-
cer, suggest an association between en-
zyme level and disease spread. The find-
ings were independent of age, sex, site of
cancer and histological type, and mean
SACE was not correlated to pulmonary
function. Furthermore, despite a signi-
ficant correlation between SACE and
operability at preoperative evaluation,
the strongest correlation was seen after
up to 22 months of observation. These
results suggest that factors contributing
to the low SACE may in part be indepen-
dent of those noted at preoperative
evaluation, e.g. size and spread of cancer,
histology, age, general condition, pul-
monary function, etc.
The reason for these findings remains
speculative. With respecttotheendothelial
localization of the enzyme, a low SACE
could be caused by spread of cancer into
the pulmonary vasculature, followed by a
decreased enzyme formation, although
the discrete fall in SACE after operation
(including two patients undergoing total
pneumectomy) suggest that this purely
mechanical hypothesis is not the only
explanation. An inhibition of enzyme
formation by tumour-produced enzyme
inhibitors or by pulmonary hypoxia (Bed-
rossian et al., 1978; Stalcup et al., 1979)
was another possible explanation. How-
ever, if enzyme inhibition was involved,
increased SACE would be expected after
removal of cancer; but in fact a slight
decrease was seen. Furthermore, no corre-
lation was found between SACE and arte-
rial gas tensions.
Among patients with lung cancer as a
whole, a slight (but significant) lower
mean SACE was found when compared
with healthy controls. This is in agreement
with previous reports on lung cancer. A
decreased SACE level has also been found
in malignant lymphoproliferative and
haematological disorders in which SACE
was also associated with prognosis, though
not so regularly as observed in lung
cancer (R0mer & Emmertsen, 1980).
With regard to other lung diseases,
measurement of SACE has been mostly
used in sarcoidosis (Lancet, Editorial,
1980; R0mer, 1979), where high SACE is
presumably due to increased formation
in the monocyte macrophage-derived non-
caseating epithelioid granulomas (Silver-
stein et al., 1979).
Non-caseating epithelioid granulomas
occur in 3-400 of lung cancer patients
(Laurberg, 1975). In some cases this find-
ing can lead to an erroneous diagnosis of
sarcoidosis (R0mer, 1980b). It was remark-
able that nobody with non-caseating
epithelioid granulomas in lymph nodes
draining lung cancer had high SACE. This
suggests that measurement of SACE may
be valuable in these cases, high level of
SACE speaking strongly against cancer.
Although at present the clinical use of
SACE measurement has been restricted
to sarcoidosis, the present results indicate
a significant and perhaps useful rela-
tionship between SACE and prognosis in
lung cancer, because a low SACE seems to
indicate poor prognosis. Thus, measure-
ment of SACE may be a biochemical
marker of cancer mass, as has been pro-
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posed for carcinoembryonic antigen (Con-
cannon et al., 1978; Dent et al., 1978). The
present findings suggest that if a patient
with lung cancer has a very low SACE, one
should re-evaluate the patient with respect
to operability, even if he has been judged
as being operable by conventional criteria.
The study was supported by the Danish Medical
Research Council (Statens laegevidenskabelige
Forskningsrad), Grant No. 512-20091.
ACE-analysis was skilfully performed by labora-
tory technician Kirsten Golczyk.
Dr S. E. N0rmark Larsen, M.D., assisted with
arranging serial blood samples in patients examined
pre- and postoperatively.
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